Molecular diagnostics company Iron Horse Diagnostics announced a non-exclusive license agreement with Euroimmun Medizinische Labordiagnostika, a German company that specializes in in vitro diagnostics, to launch the first marketed ALS diagnostic test. Under the agreement, Eurimmun will launch the product in Europe, while Iron Horse will manage marketing in the U.S. The diagnostic test is based on research by Bowser and colleagues pointing to pNfH (phosphorylated axonal neurofilament subunit H) and complement c3 as diagnostic biomarkers for ALS (see Oct 2011 news, Ganesalingam et al., 2011, Ganesalingam et al., 2013). The CSF-based diagnostic test being developed by Iron Horse has been shown to be over 90% accurate, and a blood-based biomarker is undergoing further validation. These tests could significantly accelerate the timeline for an ALS diagnosis, which could improve patient care and enable earlier therapeutic interventions.
Click here to read more.